DOCSLIB.ORG

Provincial Code List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

ANNEXURE A PROVINCIAL CODE LIST CATALOGUE OF APPROVED PHARMACEUTICALS FOR USE IN THE DEPARTMENT OF HEALTH ISSUE No. 06/13 UPDATED: 03-June-2013 INCLUDES: Supplementary List No: 129 Page 1 GENERIC DESCRIPTION ATC MIMS SUPP LIST *EDL STRENGTH FORM TRADE NAME RESTRICTION COMMENT Available through the HIV/AIDS pgwc programme - for treating AIDS patients abacavir J05AF 18.12 20mg/ml solution ZIAGEN AIDS programme ARV depot according to the appropriate protocols. Also see Circular H34/2012 pgwc abacavir J05AF 18.12 300mg tablet ZIAGEN AIDS programme As above. ARV depot Specialist: neurologist, acetazolamide S01EC 16.1 A 500mg/10ml injection DIAMOX; AZOMID neurosurgeon & opthalmologist General . Supp List neurologist, acetazolamide S01EC 16.1 1 A P 250mg tablet DIAMOX General - for Glaucoma emergencies 119 neurosurgeon & ophthalmologist Initiated Supp List acetic acid S02AA Ø 1 2% in aqueous ear drops 118 acetone X Ø liquid ACETONE 40mg + 200mg/ intraocular Specialist: acetylcholine + mannitol S01EB 15.7 COVOCHOL 4,5ml injection ophthalmologist acitretin D05BB 14.5 A 10mg capsule NEOTIGASON Specialist: dermatologist acitretin D05BB 14.5 A 25mg capsule NEOTIGASON Specialist: dermatologist ACRIFLAVIN acriflavine R02AA Ø 0,1% emulsion EMULSION acyclovir J05AB 18.12 A P 250mg injection ZOVIRAX Specialist acyclovir J05AB 18.12 P 200mg/5ml suspension ZOVIRAX Specialist General: For Primary Genital Herpes, GUS, Chronic Herpetic Ulcer, Herpes Zoster, Eczema Herpeticum, Herpes General & Stomatitis and Ophthalmic Zoster: Suppl List acyclovir J05AB 18.12 1 A P 200mg tablet ZOVIRAX Clinical Nurse According to H135/2002 Addendum A - 119/122 Practitioner Supp List 92. Clinical Nurse Practitioner: according to EDL General: For Primary Genital Herpes, GUS, Chronic Herpetic Ulcer, Herpes Zoster, Eczema Herpeticum, Herpes General & Stomatitis and Ophthalmic Zoster: Suppl List acyclovir J05AB 18.12 1 A P 400mg tablet ZOVIRAX Clinical Nurse According to H135/2002 Addendum A - 119/122 Practitioner Supp List 92. Clinical Nurse Practitioner: according to EDL For ophthalmic zoster. Patients to be acyclovir S01AD 15.1.1 SL 128 A 30mg/g eye ointment ZOVIRAX referred to ophthalmologist urgently. Page 2 Supp List adenosine C01EB 7.2 A P 6mg/2ml injection ADENOCOR 122 Central hospital use at paediatric Supp List EPIPEN AUTO- allergy clinics: non-referable. History adrenaline auto-injector C01CA 5.1 0,3mg/0,3ml auto-injector Specialist paediatrician 125 INJECTOR of severe allergic reaction or anaphylaxis. Central hospital use at paediatric adrenaline auto-injector Supp List auto-injector EPIPEN JR AUTO- allergy clinics: non-referable. History C01CA 5.1 0,15mg/ 0,3ml Specialist paediatrician (junior) 125 (Junior) INJECTOR of severe allergic reaction or anaphylaxis. adrenaline B.P. C01CA 7.1.2 1 A P 1:1000 1mg/ml injection ADRENALINE For: Suppl List - Children under two years of age albendazole P02CA 13 1 A P 200mg tablet ZENTEL 119/121 - Neurocysticercosis, hydatid cysts, tape worm, sandworm For: Suppl List - Children under two years of age albendazole P02CA 13 1 A P 400mg tablet ZENTEL 119/121 - Neurocysticercosis, hydatid cysts, tape worm, sandworm albumin, normal serum B05AA Ø P 0.2 infusion Specialist paediatrician Restricted to patients with DEXA T- score ≤ -2,5 plus proven history of Supp List alendronate M05BA 4.7.1 A 10mg tablets OSTEOBON Specialist initiated osteoporotic fracture (i.e. secondary 125 prevention only).. Prescriptions to be endorsed with these criteria. Specialist physicians and alfacalcidol A11CC 20.1 P 0,25µg capsule ONE-ALPHA paediatricians initiated Specialist physicians and alfacalcidol A11CC 20.1 P 1µg capsule ONE-ALPHA paediatricians initiated alfentanil N01AH 2.1.2 A 1mg/2ml injection RAPIFEN Specialist alfentanil N01AH 2.1.2 A 5mg/10ml injection RAPIFEN Specialist Cheapest uro-selective alpha-blocker on tender to be coded. For BPH and/or LUTS: with referral to a urologist within 6 months for those patients who have alfuzosin G04CA 7.3.2 SL 129 10mg tablets XATRAL Specialist initiated not previously been on an alpha- blocker (i.e. referral within 6 months for patients initiated on an alpha-blocker for BPH / LUTS). LUTS = Lower Urinary Tract Symptoms in males. allergen-skin prick tests Supp List ALLERGEN SKIN Allergy clinics for allergy 124 PRICK TESTS allopurinol M04AA 4.2 A P 100mg tablet ZYLOPRIM; PURICOS allopurinol M04AA 4.2 300mg tablet ZYLOPRIM Page 3 alprostadil C01EA 7.5 0,5mg/ml injection PROSTIN VR Specialist: paediatrician Urology. Erectile dysfunction. Central Hospitals alprostadil G04BE 17.5.2 20µg/ml injection CAVERJECT Maximum of 4 doses. Specialist: urologist Patient name basis. For acute arterial occlusion and deep alteplase B01AD 8.3 50mg injection ACTILYSE Specialist vein thrombosis. aluminium hydrox. + A02AD 12.4 1 A 250mg + 500mg tablet GELUSIL magnesium trisil. aluminium hydrox.+ For radio-oncology patients only, non- Supp List 291mg + 98mg + magnesium hydrox. + A02AD 12.4.1 suspension MUCAINE Specialist oncologist referable. 124 10mg/5ml oxethazaine Maximum dose 10ml 4 times daily. aluminium hydroxide A02AB 12.4 A 300mg/5ml suspension AMPHOGEL Specialist initiated SYMMETREL; amantadine HCl N04BB 1.7.1 100mg capsule Specialist: neurologist ANTADINE amethocaine HCl D04AB 2.2.1 0.01 cream ANETHAINE amethopterin: See methotrexate Amiloride HCl + Specialist – central hospitals, Suppl List hydrochlorothiazide C03DB 16.1 5mg + 50mg tablets MODURETIC Specialist hypertension clinic only, non-referable 128 amikacin J01GB 18.3 A P 100mg injection AMIKIN; KACINTH-A Specialist amikacin J01GB 18.3 P 250mg injection AMIKIN Specialist amikacin J01GB 18.3 A 500mg injection AMIKIN Specialist aminocaproic acid B02AA 8.1 A 250mg/ml injection AMICAR aminophylline I.V. R03DA 10.2.2 1 A P 250mg/10ml injection PETERPHYLLIN Genreal code: cardiovascular General amiodarone HCl C01BD 7.2 A 150mg/3ml injection CORDARONE X resuscitation Specialist Specialist physician physician: other indications amiodarone HCl C01BD 7.2 A 200mg tablet CORDARONE X Specialist physician For patients who have not responded to or experienced intolerable side Specialist psychiatrist Suppl List effects with other coded anti- amisulpiride N05AL 1.5.3 50mg tablet SOLIAN initiated with annual 116 psychotics. review with psychiatrist To be used in line with the Mental Health protocol For patients who have not responded to or experienced intolerable side Specialist psychiatrist Suppl List effects with other coded anti- amisulpiride N05AL 1.5.3 200mg tablet SOLIAN initiated with annual 116 psychotics. review with psychiatrist To be used in line with the Mental Health protocol TRYPTANOL; amitriptyline N06AA 1.4.1 1 A P 10mg tablet TREPILINE amitriptyline N06AA 1.4.1 1 A P 25mg tablet TRYPTANOL Supp List amlodipine C08CA 7.3.7 114 and 1 A 5mg tablet NORVASC 119 Supp List NORVASC; amlodipine C08CA 7.3.7 1 A 10mg tablet 120 AMIODAC 10 Page 4 amoxycillin J01CA 18.1.1 1 A P 250mg capsule AMOXIL; MOXYPEN amoxycillin J01CA 18.1.1 1 A 500mg capsule AMOXIL To use cheapest pack size on tender. amoxycillin J01CA 18.1.1 1 P 125mg/5ml suspension AMOXIL amoxycillin J01CA 18.1.1 1 P 250mg/5ml suspension AMOXIL amoxycillin + clavulanic acid: see co-amoxyclav amphotericin-B J02AA 18.8 A P 50mg injection FUNGIZONE PETERCILLIN; ampicillin J01CA 18.1.1 P 250mg injection AMPIPEN ampicillin J01CA 18.1.1 A P 500mg injection PETERCILLIN Specialist oncologist For second line treatment for anastrazole L02BG 19.8 SL127 1mg tablets ARIMIDEX, STRADEXA initiated Tamoxifen intolerant patients. Maximum one bottle per patient per antazoline + 0,05% + month. S01GA 15.4 eye drops SPERSALLERG tetrahydrozoline 0,04% ALTERNATIVE: Item Above. Cheapest on tender will be used. 500 000 iu/50ml aprotinin B02AB 27 1 000 000 injection TRASYLOL Central hospitals only, not referable. iu/100ml aqueous cream D02AC Ø 1 B.P. cream AQUEOUS CREAM aqueous cream D02AC Ø B.P. cream AQUEOUS CREAM artemether + Supp List P01BE 18.11 1 20mg / 120mg tablets COARTEM lumefantrine 120 ascorbic acid: See Vitamin C Supp List 1 Not repeatable for acute conditions aspirin soluble N02BA 3.2 300mg tablet DISPRIN 115 A (short course) Supp list As per Health Programmes protocol - atazanavir J05AE 18.12 150mg capsule REYATAZ 126 refer to circular H148/2011 Supp list As per Health Programmes protocol - atazanavir J05AE 18.12 150mg capsule REYATAZ 126 refer to circular H148/2011 atenolol C07AB 7.4 A 5mg/10ml injection TENORMIN Specialist atenolol C07AB 7.4 1 A P 50mg tablet TENORMIN; ATEROL General: ARV clinics only, according to Health Programmes' algorithm for the management of dyslipidaemia General - ARV clinics Specialist physician initiated: Familial Supp List only atorvastatin C10AA 7.7.2 10mg tablet LIPITOR heterozygous hypercholesterols and 116/124 Specialist physician familial homozygous initiated hypercholesterolemia patients who do not tolerate simvastatin. 3) Familial homozygous hypercholesterolemia (doses of 40mg and higher) Page 5 1) For HIV/AIDS patients. 2) Familial heterozygous hypercholesterols and familial homozygous Supp List Specialist physician atorvastatin C10AA 7.7.2 20mg tablet LIPITOR hypercholesterolemia patients who do 116/124 initiated not tolerate simvastatin. 3) Familial homozygous hypercholesterolemia (doses of 40mg and higher) Supp List Specialist physician atorvastatin C10AA 7.7.2 40mg tablet LIPITOR As above 116/124 initiated Supp List Specialist physician atorvastatin C10AA 7.7.2 80mg tablet LIPITOR As above 116/124 initiated atropine sulphate A03BA 5.4 1 A P 0,5mg/ml injection SABAX ATROPINE atropine
Recommended publications
  • United States Patent 19 11 Patent Number: 5,648,064 Gaffar Et Al

    United States Patent 19 11 Patent Number: 5,648,064 Gaffar Et Al

    US005648064A United States Patent 19 11 Patent Number: 5,648,064 Gaffar et al. 45 Date of Patent: Jul. 15, 1997 (54) ORAL COMPOSITIONS HAVING 5,279,816 1/1994 Church et al. ............................ 424/53 ACCELERATED TOOTH WHTENING 5,302,374 4/1994 Wagner ..................................... 424/52 EFFECT 5,302,375 4/1994 Viscio ....................................... 424/53 5,356,554 10/1994 Delwel et al. ........................... 252/94 I76) Inventors: Abdul Gaffar, 89 Carter Rd., Princeton, 5,536,441 7/1996 Chapple et al. ................... 252A186.33 N.J. 08902; Sahar Fakhry-Smith. 7 FOREIGN PATENT DOCUMENTS Ryans Ct. Bordentown, N.J. 08505 0237111 9/1987 European Pat. Off. ......... C11D 3/39 (21) Appl. No.: 499,532 Primary Examiner-Shep K. Rose Attorney, Agent, or Firm-Paul Shapiro (22 Filed: Jul. 7, 1995 57 ABSTRACT (51] Int. Cl. .................. A61K 7/16; A61K7/20 52 U.S. Cl. ............................................... 424/53; 424/49 A two component whitening dentifrice composition is dis 58) Field of Search ................................... 424/53. 49-58 closed which comprises a first component containing a peroxygen compound such as hydrogen peroxide and a (56) References Cited second dentifrice component containing a manganese coor dination complex compound such as manganese gluconate, U.S. PATENT DOCUMENTS which activates the peroxygen compound and accelerates 4,728,455 3/1988 Rerek ........................................ 25299 the release of active oxygen for rapid whitening action, the 4,759,956 7/1988 Amer et al. ... 427/213 first and second components being maintained separate from 5,032,178 7/1991 Cornell ..................................... 106/35 the other until dispensed for application to teeth. 5, 194416 3/1993 Jureller et al.
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • Laboratory Reagents Product List 2021

    Laboratory Reagents Product List 2021

    PRODUCT LIST Examples of our laboratory reagents Product list – selected products Artificial Urine Brooks and Keevil AMPQ44861.1000 Auramine-Rhodamine AMPQ55029.0500 Below is a selection of products. If you cannot find what you are look- Auric Chloride 0.1% AMPQ12450.0500 ing for, please contact us about your specific requests for laboratory reagents, volume and packaging, etc. Auric Chloride 1% AMPQ12452.0100 We mainly use chemicals by p.a. quality. If you want growth control on growing media, please contact us for an offer. B Balanced Salt Solution for Storage AMPQ46214.0100 Product name Cat. No. Balanced Salt Solution with Tris AMPQ40040.1000 Barium Chloride 0.5 M = 1.0 N AMPQ42099.1000 2,4-Dinitroflouro Benzen 1.3% v/v AMPQ44913.0100 Barium Chloride 1 M AMPQ43551.0500 2-Amino-2-Methyl-1,3-propanediol 2.1 % w/v AMPQ42009.0250 Barium Chloride 10% w/v AMPQ10513.1000 2-Propanol 35% AMPQ12900.5000 Barium Diphenylamine Sulfonate AMPQ40838.0500 Basophil Counting Solution AMPQ90492.0200 A Basophilic Colouring Solution AMPQ42037.0100 Acetate Buffer 0.1 M, pH 4.0 AMPQ10021.1000 Benzamidine 0.5 M in MilliQ H2O AMPQ10750.0100 Acetate Buffer 0.1 M, pH 4.8 AMPQ40728.1000 Benzoe I Colouring Solution AMPQ10779.0100 Acetate Buffer 0.1 M, pH 5.9 AMPQ43009.1000 Benzoe II Colouring Solution AMPQ10781.0100 Acetate Buffer 35%, pH 5.6 AMPQ10015.1000 Biebrich Scarlet Solution AMPQ46088.1000 Acetate Buffer Walpole pH 4.1 AMPQ55005.0500 Biebrich's Scarlet Acid Fuchsin AMPQ29082.0500 Acetic Acid 0.1 M Titrated AMPQ11590.5000 Bies Colouring Solution AMPQ10780.0050 Acetic Acid 1% AMPQ11515.1000 BiGGY Agar AMPQ02048.0015 Acetic Acid 10% P.A.
  • Surface Morphology Alterations in Bovine Dentin Exposed to Different Bleaching Agents

    Surface Morphology Alterations in Bovine Dentin Exposed to Different Bleaching Agents

    Braz J Oral Sci. Original Article January/March 2009 - Volume 8, Number 1 Surface morphology alterations in bovine dentin exposed to different bleaching agents Juliana Nascimento Santos1, Daniel Pinto de Oliveira1, Fábio Roberto Dametto1, Brenda Paula Figueiredo de Almeida Gomes2, Alexandre Augusto Zaia2, José Flávio Affonso de Almeida2, Caio Cezar Randi Ferraz2 1 DDS, MSc, PhD, Department of Restorative Dentistry and Endodontics, Faculdade de Odontologia de Piracicaba, Universidade Estadual de Campinas (Unicamp), Piracicaba (SP), Brazil 2 DDS, MSc, PhD, Professor, Department of Restorative Dentistry, Endodontics, Faculdade de Odontologia de Piracicaba, Unicamp, Piracicaba (SP), Brazil Abstract Aim: This study evaluated the morphological changes caused by internal bleaching agents on dentin surface. Methods: Twenty crowns of bovine incisors were cut into slabs that were randomly distributed in six experimental groups (n = 5), according to the bleaching agent used: G1 – sodium perborate + water, G2 – sodium perborate + 2% chlorhexidine gel, G3 – sodium perborate + 30% hydrogen peroxide, G4 – 30% hydrogen peroxide, G5 – 37% carbamide peroxide and G6 – gel base without carbamide. Two Control Groups were used: C1 with distilled water and C2 with 2% chlorhexidine gel. The specimens were immersed in the respective test bleaching agent and incubated at 37 °C for seven days. Following, they were prepared for scanning electron microscopy and five images from each tooth segment were recorded and analyzed for surface morphological alterations, by three previously calibrated examiners. Inter-examiner agreement was verified using the Kappa test. The rank averages obtained for the groups were subjected to Kruskal-Wallis analysis of variance at 5% significance level. Results: The analysis of the scores obtained indicated that all tested materials caused some morphological alteration on dentin, except for sodium perborate + water (G1) and Control Groups 1 and 2.
  • Ammonium-Persulphate.Pdf

    Ammonium-Persulphate.Pdf

    ADVANCE An Exclusive Chemical Range CHEMICAL SALES CORPORATION CHEMICAL SUPPLIES SIMPLIFIED ABOUT US ADVANCE CHEMICAL SALES CORPORATION Advance Chemical Sales Corporation is an industrial distributor of Fine & Speciality Chemicals. It boasts of its technology-driven innovative ways in suppling products to its customers. ADVANCE CHEMICAL SALES CORPORATION (ACSC) has been a trusted supplier of chemicals since 1968. We like to work alongside customers and solve their challenges with efficiency, progressive solutions and quality products. Whether the order is for chemical commodities or speciality chemicals, no matter if the volume is large or small, we can handle it. We are committed to bring the best quality products at competitive prices from reputed manufacturers to our customers. Our goal is to make sure that our customers find their needs of chemicals in one place. We work to develop the customers' trust An Exclusive Chemical Range EXEMPLAR DELHI is in Trade and Import of ACIDS, INORGANIC CHEMICALS, METAL ORGANIC COMPOUNDS, ORGANIC CHEMICALS & SOLVENTS. EXEMPLAR NOIDA produces chemicals like ACETATES, CHELATED EDTA, CITRATES, EDTA SALTS, GLUCONATES, HEDP SALTS, OXALATES, PHOSPHATES, TARTRATES, FINE & PERFORMANCE CHEMICALS INDUSTRIES SERVED AGRO CHEMICALS DAIRY PAINTS & INKS CERAMIC & GLASS DETERGENTS PESTICIDES CHEMICAL INDUSTRIES FOOD PROCESSING PHARMACEUTICALS CONSTRUCTION LUBRICANTS POULTRY FEED COSMETICS METAL TREATMENT WATER TREATMENT CHEMICAL SUPPLIES SIMPLIFIED ACETATES AGRO CHEMICALS Ammonium acetate Amino acid (Protein hydrolysate) Calcium acetate Boron-20 Potassium acetate Disodium octaborate tetrahydrate Sodium acetate 3 hyd. Fulvic acid Sodium acetate anhy. Potassium humate Sodium diacetate Potassium humate fulvate Zinc acetate 2 hy. Seaweed extract ACIDS ALKALIES Acetic acid glacial Alumina trihydrate Adipic acid Aluminium oxide (Calcined) Ascorbic acid Ammonia solution Benzoic acid Ammonium carbonate Boric acid Calcium carbonate Citric acid mono/ anhy.
  • The Treatment of Acute Neerotizing Ulcerative Gingivitis Anne C

    The Treatment of Acute Neerotizing Ulcerative Gingivitis Anne C

    Penodontics The treatment of acute neerotizing ulcerative gingivitis Anne C. Hartnett* / Jacob Shiloah** The destruction of tbe interdental papillae and formation of permanent gingiva! craierx are common sequelae of acute neerotizing uleerative gingivitis. These craters ean be disfiguring, especially in the anterior gingiva, and ean act as a nidus for recurrent epi- sodes. Traditional therapy has emphasized a stirgieal approach for elimination of Ihese defects, often increasing the esthelie problems. The pwpose of this paper is to review the treatment modalities of acitte neerotizing itlcerative gingivitis and ¡Ilústrate an al- ternative treatment approach of periodic sealing, root planing, and antimicrohiai rinses with 0.12% chlorhexidine. With this therapeutic regimen, the disease proeess ean be reversed and damaged papillae may regenérale. (Quintessence Int 1991:22:95-100.) Introduction chetes, fusifonn bacteria, and species of Bacteroides are the organisms most frequently cultivated from Acute neerotizing ulcerative gingivitis (ANUG) is a these lesions,' a definitive periodontal pathogen has rapidly destructive, noncommunicable, gingival infec- yet to be tmplicated in the onset or progression of tion of complex etiology. It is characterized by necrosis ANUG. A susceptible animal model in which to study of the crest of the gingival papillae, spontaneous ANUG has not been found. bleeding, pain, and halitosis. If left untreated, it may Previous studies have speculated on the importance spread laterally and apically to involve the entire
  • Entodinternational.Com ENTOD HOUSE, W-50(B), M.I.D.C, T.T.C

    Entodinternational.Com ENTOD HOUSE, W-50(B), M.I.D.C, T.T.C

    Since 1977... Ocular Care & Wellness Since 1977 OUR OPHTHALMIC • Over 40 Years of Pharmaceutical & Nutraceutical Expertise RANGE AT A GLANCE • International Formulation R&D Centres • Technology-Driven Ophthalmics • WHO GMP & US FDA Accredited Manufacturing • Global Exports CONTACT US Head Office: Entod Pharmaceuticals Ltd., OPHTHALMIC FORMULATIONS R & D OPHTHALMIC SPECIALTY EXCIPIENTS Ashirwad Building, S.V. Road, Opp. Badi Masjid, Bandra(W), Mumbai-400050, INDIA Email: [email protected] Additional Office: 15 Tottenham Lane, London N8 9DJ, UK. E-mail: [email protected] A Global Research-Based Speciality Website: ophthalmicsuk.com Formulation R&D: Pharmaceutical Enterprise Medisearch Laboratory entodinternational.com ENTOD HOUSE, W-50(B), M.I.D.C, T.T.C. Indl. Estate, Rabale, Thane-Belapur Road, Follow us on: Navi Mumbai-400701, INDIA Email: [email protected] @entodinternational @entodpharma Entod Pharmaceuticals Medisearch Laboratories Entod Research 2018073 Ltd. (India) (Bombay) Pvt. Ltd. (India) Cell Ltd. (UK) entodinternational.com entodinternational.com Complete Ophthalmic Finished Products Range PRESS-DT TABLET OMEFLOX-BM EYE DROPS EYETAMIN CAPSULES MYOPIA CONTROL Acetazolamide IP 250mg Ofloxacin IP 0.3% w/w Lycopene, Lutein Zeaxanthin, Betamethasone Sodium Phosphate 0.1% w/w Vitamins & Minerals MYATRO EYE DROPS ENDOR EYE DROPS FLUCOCID EYE DROPS Fluconazole USP 0.3% w/v Atropine Sulphate USP 0.01% w/v Dorzolamide HCl USP 2% w/v TOBRACID-F EYE DROPS I-DEW MEGA CAPSULES Stabilized Oxychloro Complex 0.005% w/v Benzalkonium Chloride Solution IP 0.0075%w/v NATACIN EYE DROPS Tobramycin Sulphate USP Omega 3 fatty acid (deodourised) eqv. To ENDOR PLUS EYE DROPS Natamycin USP 5.0%w/v equi.
  • Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008

    Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008

    Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008 Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008 William A. Rutala, Ph.D., M.P.H.1,2, David J. Weber, M.D., M.P.H.1,2, and the Healthcare Infection Control Practices Advisory Committee (HICPAC)3 1Hospital Epidemiology University of North Carolina Health Care System Chapel Hill, NC 27514 2Division of Infectious Diseases University of North Carolina School of Medicine Chapel Hill, NC 27599-7030 1 Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008 3HICPAC Members Robert A. Weinstein, MD (Chair) Cook County Hospital Chicago, IL Jane D. Siegel, MD (Co-Chair) University of Texas Southwestern Medical Center Dallas, TX Michele L. Pearson, MD (Executive Secretary) Centers for Disease Control and Prevention Atlanta, GA Raymond Y.W. Chinn, MD Sharp Memorial Hospital San Diego, CA Alfred DeMaria, Jr, MD Massachusetts Department of Public Health Jamaica Plain, MA James T. Lee, MD, PhD University of Minnesota Minneapolis, MN William A. Rutala, PhD, MPH University of North Carolina Health Care System Chapel Hill, NC William E. Scheckler, MD University of Wisconsin Madison, WI Beth H. Stover, RN Kosair Children’s Hospital Louisville, KY Marjorie A. Underwood, RN, BSN CIC Mt. Diablo Medical Center Concord, CA This guideline discusses use of products by healthcare personnel in healthcare settings such as hospitals, ambulatory care and home care; the recommendations are not intended for consumer use of the products discussed. 2
  • Food and Drugs

    Food and Drugs

    21 Part 170 to 199 Revised as of April 1, 2001 Food and Drugs Containing a codification of documents of general applicability and future effect As of April 1, 2001 With Ancillaries Published by Office of the Federal Register National Archives and Records Administration A Special Edition of the Federal Register VerDate 11<MAY>2000 11:38 Apr 16, 2001 Jkt 194064 PO 00000 Frm 00001 Fmt 8091 Sfmt 8091 Y:\SGML\194064F.XXX pfrm02 PsN: 194064F U.S. GOVERNMENT PRINTING OFFICE WASHINGTON : 2001 For sale by the Superintendent of Documents, U.S. Government Printing Office Internet: bookstore.gpo.gov Phone: (202) 512-1800 Tax: (202) 512-2250 Mail Stop: SSOP, Washington, DC 20402–0001 VerDate 11<MAY>2000 11:38 Apr 16, 2001 Jkt 194064 PO 00000 Frm 00002 Fmt 8092 Sfmt 8092 Y:\SGML\194064F.XXX pfrm02 PsN: 194064F Table of Contents Page Explanation ................................................................................................ v Title 21: Chapter I—Food and Drug Administration, Department of Health and Human Services (Continued) ................................................. 3 Finding Aids: Material Approved for Incorporation by Reference ............................ 573 Table of CFR Titles and Chapters ....................................................... 587 Alphabetical List of Agencies Appearing in the CFR ......................... 605 Redesignation Table ............................................................................ 615 List of CFR Sections Affected ............................................................. 617
  • The International Pharmacopoeia

    The International Pharmacopoeia

    The International Pharmacopoeia THIRD EDITION Pharmacopoea internationalis Editio tertia Volume 4 Tests, methods, and general requirements Quality specifications for pharmaceutical substances, excipients, and dosage forms World Health Organization Geneva 1994 WHO Library Cataloguing in Publication Data The International Pharmacopoeia.- 3rd ed. Contents: v. 4. Tests, methods, and general requirements 1. Drugs -analysis 2. Drugs -standards ISBN 92 4 154462 7 (NLM Classification: QV 25) The World Health Organization welcomes requests for permission to reproduce or translate its publica- tions, in part or in full. Applications and enquiries should be addressed to the Of£ice of Publications, World Health Organization, Geneva, Switzerland, which will be glad to provide the latest information on any changes made to the text, plans for new editions, and reprints and translations already available. O World Health Organization, 1994 Publications of the World Health Organization enjoy copyright protection in accordance with the provi- sions of Protocol 2 of the Universal Copyright Convention. All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distin- guished by initial capital letters.
  • Estonian Statistics on Medicines 2016 1/41

    Estonian Statistics on Medicines 2016 1/41

    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
  • Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services

    Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services

    Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services Australian Statistics on Medicines 1997 i © Commonwealth of Australia 1998 ISBN 0 642 36772 8 This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be repoduced by any process without written permission from AusInfo. Requests and enquiries concerning reproduction and rights should be directed to the Manager, Legislative Services, AusInfo, GPO Box 1920, Canberra, ACT 2601. Publication approval number 2446 ii FOREWORD The Australian Statistics on Medicines (ASM) is an annual publication produced by the Drug Utilisation Sub-Committee (DUSC) of the Pharmaceutical Benefits Advisory Committee. Comprehensive drug utilisation data are required for a number of purposes including pharmacosurveillance and the targeting and evaluation of quality use of medicines initiatives. It is also needed by regulatory and financing authorities and by the Pharmaceutical Industry. A major aim of the ASM has been to put comprehensive and valid statistics on the Australian use of medicines in the public domain to allow access by all interested parties. Publication of the Australian data facilitates international comparisons of drug utilisation profiles, and encourages international collaboration on drug utilisation research particularly in relation to enhancing the quality use of medicines and health outcomes. The data available in the ASM represent estimates of the aggregate community use (non public hospital) of prescription medicines in Australia. In 1997 the estimated number of prescriptions dispensed through community pharmacies was 179 million prescriptions, a level of increase over 1996 of only 0.4% which was less than the increase in population (1.2%).